Angel Baldán

Summary

Affiliation: Saint Louis University
Country: USA

Publications

  1. pmc Anti-miR-33 therapy does not alter the progression of atherosclerosis in low-density lipoprotein receptor-deficient mice
    Tyler J Marquart
    Edward A Doisy Department of Biochemistry and Molecular Biology, Saint Louis University School of Medicine, Saint Louis, MO 63104, USA
    Arterioscler Thromb Vasc Biol 33:455-8. 2013

Collaborators

  • Tyler J Marquart
  • Aldons J Lusis
  • Judy Wu

Detail Information

Publications1

  1. pmc Anti-miR-33 therapy does not alter the progression of atherosclerosis in low-density lipoprotein receptor-deficient mice
    Tyler J Marquart
    Edward A Doisy Department of Biochemistry and Molecular Biology, Saint Louis University School of Medicine, Saint Louis, MO 63104, USA
    Arterioscler Thromb Vasc Biol 33:455-8. 2013
    ..To determine the efficacy of long-term anti-miR-33 therapy on the progression of atherosclerosis in high-fat, high-cholesterol-fed Ldlr(-/-) mice...